Tradestie Institutional Equity Comparison Engine

SGP vs BMY โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BMY Overall Edge

BMY Captures Institutional Edge (4โ€“0 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Bristol-Myers Squibb Co. (BMY) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, SGP trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus BMY at 9.4x Forward P/E and 32.4% operating margin (+6.9% YoY). In options structure, SGP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BMY sits in CONSOLIDATION (31st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner BMY
SGP N/M vs BMY 9.4x Fwd P/E
Growth & Margin Winner BMY
Op Margin N/A vs 32.4% ยท YoY N/A vs +6.9%
Momentum & Technical Winner BMY
1Y +22.1% vs +29.4% ยท 52W Pos 66% vs 76%
Options & Structure Winner BMY
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (31st %ile IV)
SGP US Equity
SGP
Institutional Equity
$32.24
-1.95% 1D
Market Cap N/A
1M Return +34.33%
1Y Return +22.12%
Forward P/E N/M
Unified AI Score
39.3 / 100 SELL
Tech 15.0 Fund 45.0 Flow 50.0 Mom 60.0
BMY NYSE
Bristol-Myers Squibb Co.
Pharmaceutical Preparations
$62.93
-0.79% 1D
Market Cap $129.7B
1M Return +5.32%
1Y Return +29.41%
Forward P/E 9.4x
Unified AI Score
53.5 / 100 HOLD
Tech 50.0 Fund 58.0 Flow 70.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SGP +22.12% BMY +29.41% Spread: +20.6 pp (SGP Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SGP TTM Op. Margin: N/A BMY TTM Op. Margin: 32.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SGP vs BMY. Trailing 12-month operating profitability (SGP N/A vs BMY 32.4%) and valuation multiples (SGP N/M vs BMY 9.4x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SGP (0) vs BMY (10)
Institutional Metric SGP BMY Criterion Row Winner
Market Capitalization Scale N/A $129.7B Larger Scale BMY
Trailing P/E Ratio Valuation N/M 14.1x Lower Multiple BMY
Forward P/E Ratio Valuation N/M 9.4x Lower Multiple BMY
Revenue Growth (YoY) Growth N/A +6.9% Higher Growth BMY
Operating Margin (TTM) Profitability N/A 32.4% Higher Margin BMY
Net Profit Margin Profitability N/A 18.5% Higher Margin BMY
Return on Equity (ROE) Capital Efficiency N/A 44.0% Higher ROE BMY
52-Week Range Position Momentum 66% ($17โ€“$40) 76% ($45โ€“$69) Stronger Trend BMY
Beta / 30D Volatility Risk Regime 1.38ฮฒ ยท 70% Vol 0.17ฮฒ ยท 31% Vol Lower Realized Risk BMY
Unified Institutional Score Composite Signal 39.3 / 100 (SELL) 53.5 / 100 (HOLD) Higher Composite BMY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SGP vs BMY Buy Guide
SGP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live SGP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BMY CONSOLIDATION
51d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 31st %ile
IV Regime Balanced (25thโ€“60th %ile)
Live BMY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SGP nor BMY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.